Immunopotentiation for bacterial biodefense

Current Topics in Medicinal Chemistry

Volumn 14, Issue 18, 2014, Pages 2115-2126

  Skyberg, Jerod A ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Anthrax; Biodefense; Brucellosis; Glanders; Immunotherapy; Melioidosis; Plague; Tularemia

Indexed keywords

CARBOHYDRATE BINDING PROTEIN; CYTOKINE; ICOSANOID; TOLL LIKE RECEPTOR; TOXIN; CELL SURFACE RECEPTOR; CYTOKINE RECEPTOR; IMMUNOLOGIC FACTOR;

ANTHRAX; ARTICLE; BACTERIAL INFECTION; BRUCELLOSIS; GLANDERS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MELIOIDOSIS; NONHUMAN; PLAGUE; PROTEIN SYNTHESIS; Q FEVER; SIGNAL TRANSDUCTION; TULAREMIA; TYPHUS; AGONISTS; ANIMAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY;

ANIMALS; ANTHRAX; BRUCELLOSIS; GENE EXPRESSION; GLANDERS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MELIOIDOSIS; PLAGUE; Q FEVER; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOKINE; TOLL-LIKE RECEPTORS; TULAREMIA;

EID: 84926349597     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141106162642     Document Type: Article

References (140)

1. Christian, M.D. Biowarfare and bioterrorism. Crit. Care Clin., 2013, 29 (3), 717-756.
2. WHO Group of Consultants. Health aspects of chemical and biological weapons. World Health Organization: Geneva, Switzerland, 1970.
3. Kaufmann, A.F.; Meltzer, M.I.; Schmid, G.P. The economic impact of a bioterrorist attack: Are prevention and postattack intervention programs justifiable? Emerg. Infect. Dis., 1997, 3 (2), 83-94.
4. Yang, X.; Skyberg, J.A.; Cao, L.; Clapp, B.; Thornburg, T.; Pascual, D.W. Progress in vaccine development. Front. Biol. (Beijing) 2013, 8 (1), 60-77.
5. Balder, R.; Lipski, S.; Lazarus, J.J.; Grose, W.; Wooten, R.M.; Hogan, R.J.; Woods, D.E.; Lafontaine, E.R. Identification of Burkholderia mallei and Burkholderia pseudomallei adhesins for human respiratory epithelial cells. BMC. Microbiol., 2010, 10, 250.
6. Anderson, P.D.; Bokor, G. Bioterrorism: Pathogens as weapons. J. Pharm. Pract., 2012, 25 (5), 521-529.
7. Daya, M.; Nakamura, Y. Pulmonary disease from biological agents: Anthrax, plague, Q fever, and tularemia. Crit. Care Clin., 2005, 21 (4), 747-63, vii.
8. Skyberg, J.A.; Rollins, M.F.; Holderness, J.S.; Marlenee, N.L.; Schepetkin, I.A.; Goodyear, A.; Dow, S.W.; Jutila, M.A.; Pascual, D.W. Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections. PLoS. Pathog., 2012, 8 (3), e1002587.
9. Galimand, M.; Carniel, E.; Courvalin, P. Resistance of Yersinia pestis to antimicrobial agents. Antimicrob. Agents Chemother., 2006, 50 (10), 3233-3236.
10. Streptomycin Sulfate. In AHFS Drug Information Handbook, McEvoy, G.K.; Ed. The American Society of Health-System Pharmacists: Bethesda, MD, 2006, pp 71-73.
11. Alibek, K.; Handelman, S. Biohazard; Random House: New York, NY, 1999, pp. 29-38.
12. Cowley, S.C.; Elkins, K.L. Immunity to Francisella. Front. Microbiol., 2011, 2, 26.
13. Anisimov, A.P.; Amoako, K.K. Treatment of plague: Promising alternatives to antibiotics. J. Med. Microbiol., 2006, 55 (Pt 11), 1461-1475.
14. Lyons, C.R.; Lovchik, J.; Hutt, J.; Lipscomb, M.F.; Wang, E.; Heninger, S.; Berliba, L.; Garrison, K. Murine model of pulmonary anthrax: Kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun., 2004, 72 (8), 4801-4809.
15. Troyer, R.M.; Propst, K.L.; Fairman, J.; Bosio, C.M.; Dow, S.W. Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine, 2009, 27 (33), 4424-4433.
16. Rozak, D.A.; Gelhaus, H.C.; Smith, M.; Zadeh, M.; Huzella, L.; Waag, D.; Adamovicz, J.J. CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J. Immune. Based. Ther. Vaccines, 2010, 8 (1), 2.
17. Skyberg, J.A. Immunotherapy for tularemia. Virulence, 2013, 4 (8), 859-870.
18. Hickey, A.J.; Lin, J.S.; Kummer, L.W.; Szaba, F.M.; Duso, D.K.; Tighe, M.; Parent, M.A.; Smiley, S.T. Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection. Infect. Immun., 2013, 81 (6), 2123-2132.
19. D'Elia, R.V.; Harrison, K.; Oyston, P.C.; Lukaszewski, R.A.; Clark, G.C. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol., 2013, 20 (3), 319-327.
20. D'Elia, R.V.; Laws, T.R.; Carter, A.; Lukaszewski, R.; Clark, G.C. Targeting the "Rising DAMP" during a Francisella tularensis infection. Antimicrob. Agents Chemother., 2013. 57 (9) 4222-4228.
21. Tay, T.F.; Maheran, M.; Too, S.L.; Hasidah, M.S.; Ismail, G.; Embi, N. Glycogen synthase kinase-3β inhibition improved survivability of mice infected with Burkholderia pseudomallei. Trop. Biomed., 2012, 29 (4), 551-567.
22. Zhang, P.; Katz, J.; Michalek, S.M. Glycogen synthase kinase-3β(GSK3β) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Mol. Immunol., 2009, 46 (4), 677-687.
23. Wilson, C.N.; Vance, C.O.; Doyle, T.M.; Brink, D.S.; Matuschak, G.M.; Lechner, A.J. A novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with Yersinia pestis. Innate. Immun., 2012, 18 (3), 373-389.
24. Munford, R.S. Sensing gram-negative bacterial lipopolysaccharides: A human disease determinant? Infect. Immun., 2008, 76 (2), 454-465.
25. Haag, A.F.; Myka, K.K.; Arnold, M.F.; Caro-Hernandez, P.; Ferguson, G.P. Importance of Lipopolysaccharide and Cyclic_-1,2-Glucans in Brucella-Mammalian Infections., Int. J. Microbiol., 2010, 2010, 124509.
26. Novem, V.; Shui, G.; Wang, D.; Bendt, A.K.; Sim, S.H.; Liu, Y.; Thong, T.W.; Sivalingam, S.P.; Ooi, E.E.; Wenk, M.R.; Tan, G. Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis., Clin. Vaccine Immunol., 2009, 16 (10), 1420-1428.
27. Toman, R.; Garidel, P.; Andra, J.; Slaba, K.; Hussein, A.; Koch, M.H.; Brandenburg, K. Physicochemical characterization of the endotoxins from Coxiella burnetii strain Priscilla in relation to their bioactivities. BMC. Biochem., 2004, 5, 1.
28. Shannon, J.G.; Howe, D.; Heinzen, R.A. Virulent Coxiella burnetii does not activate human dendritic cells: Role of lipopolysaccharide as a shielding molecule., Proc. Natl. Acad. Sci. U. S. A, 2005, 102 (24), 8722-8727.
29. Gunn, J.S.; Ernst, R.K. The structure and function of Francisella lipopolysaccharide. Ann. N.Y. Acad. Sci., 2007, 1105, 202-218.
30. Montminy, S.W.; Khan, N.; McGrath, S.; Walkowicz, M.J.; Sharp, F.; Conlon, J.E.; Fukase, K.; Kusumoto, S.; Sweet, C.; Miyake, K.; Akira, S.; Cotter, R.J.; Goguen, J.D.; Lien, E. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol., 2006, 7 (10), 1066-1073.
31. Brett, P.J.; Burtnick, M.N.; Snyder, D.S.; Shannon, J.G.; Azadi, P.; Gherardini, F.C. Burkholderia mallei expresses a unique lipopolysaccharide mixture that is a potent activator of human Tolllike receptor 4 complexes. Mol. Microbiol., 2007, 63 (2), 379-390.
32. Skyberg, J.A.; Thornburg, T.; Rollins, M.; Huarte, E.; Jutila, M.A.; Pascual, D.W. Murine and bovine__T cells enhance innate immunity against Brucella abortus infections., PLoS One, 2011, 6 (7), e21978.
33. Silva, E.B.; Dow, S.W. Development of Burkholderia mallei and pseudomallei vaccines. Front. Cell. Infect. Microbiol., 2013, 3, 10.
34. Voth, D.E.; Heinzen, R.A. Lounging in a lysosome: The intracellular lifestyle of Coxiella burnetii. Cell. Microbiol., 2007, 9 (4), 829-840.
35. Ray, K.; Marteyn, B.; Sansonetti, P.J.; Tang, C.M. Life on the inside: The intracellular lifestyle of cytosolic bacteria. Nat. Rev. Microbiol., 2009, 7 (5), 333-340.
36. Brennan, R.E.; Russell, K.; Zhang, G.; Samuel, J.E. Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections. Infect. Immun., 2004, 72 (11), 6666-6675.
37. Lukaszewski, R.A.; Kenny, D.J.; Taylor, R.; Rees, D.G.; Hartley, M.G.; Oyston, P.C. Pathogenesis of Yersinia pestis infection in BALB/c mice: Effects on host macrophages and neutrophils. Infect. Immun., 2005, 73 (11), 7142-7150.
38. Tonello, F.; Zornetta, I. Bacillus anthracis factors for phagosomal escape. Toxins. (Basel) 2012, 4 (7), 536-553.
39. Ribot, W.J.; Panchal, R.G.; Brittingham, K.C.; Ruthel, G.; Kenny, T.A.; Lane, D.; Curry, B.; Hoover, T.A.; Friedlander, A.M.; Bavari, S. Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect. Immun., 2006, 74 (9), 5029-5034.
40. Weiner, Z.P.; Ernst, S.M.; Boyer, A.E.; Gallegos-Candela, M.; Barr, J.R.; Glomski, I.J. Circulating lethal toxin decreases the ability of neutrophils to respond to Bacillus anthracis. Cell. Microbiol., 2014, 16 (4), 504-518.
41. Roop, R.M.; Gaines, J.M.; Anderson, E.S.; Caswell, C.C.; Martin, D.W. Survival of the fittest: How Brucella strains adapt to their intracellular niche in the host. Med. Microbiol. Immunol., 2009, 198 (4), 221-238.
42. Skendros, P.; Boura, P. Immunity to brucellosis. Rev. Sci. Tech., 2013, 32 (1), 137-147.
43. Loisel-Meyer, S.; Jimenez de Bagues, M.P.; Basseres, E.; Dornand, J.; Kohler, S.; Liautard, J.P.; Jubier-Maurin, V. Requirement of norD for Brucella suis virulence in a murine model of in vitro and in vivo infection. Infect. Immun., 2006, 74 (3), 1973-1976.
44. Haine, V.; Dozot, M.; Dornand, J.; Letesson, J.J.; De Bolle, X. NnrA is required for full virulence and regulates several Brucella melitensis denitrification genes. J. Bacteriol., 2006, 188 (4), 1615-1619.
45. Baral, P.; Utaisincharoen, P. Sterile-alpha-and armadillo motifcontaining protein inhibits the TRIF-dependent downregulation of signal regulatory protein alpha to interfere with intracellular bacterial elimination in Burkholderia pseudomallei-infected mouse macrophages. Infect. Immun., 2013, 81 (9), 3463-3471.
46. Ekchariyawat, P.; Pudla, S.; Limposuwan, K.; Arjcharoen, S.; Sirisinha, S.; Utaisincharoen, P. Burkholderia pseudomalleiinduced expression of suppressor of cytokine signaling 3 and cytokine-inducible src homology 2-containing protein in mouse macrophages: A possible mechanism for suppression of the response to gamma interferon stimulation. Infect. Immun., 2005, 73 (11), 7332-7339.
47. van Schaik, E.J.; Chen, C.; Mertens, K.; Weber, M.M.; Samuel, J.E. Molecular pathogenesis of the obligate intracellular bacterium Coxiella burnetii. Nat. Rev. Microbiol., 2013, 11 (8), 561-573.
48. McCaffrey, R.L.; Schwartz, J.T.; Lindemann, S.R.; Moreland, J.G.; Buchan, B.W.; Jones, B.D.; Allen, L.A. Multiple mechanisms of NADPH oxidase inhibition by type A and type B Francisella tularensis., J. Leukoc. Biol., 2010, 88 (4), 791-805.
49. Lindgren, H.; Shen, H.; Zingmark, C.; Golovliov, I.; Conlan, W.; Sjostedt, A. Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect. Immun., 2007, 75 (3), 1303-1309.
50. Ke, Y.; Chen, Z.; Yang, R. Yersinia pestis: Mechanisms of entry into and resistance to the host cell. Front Cell. Infect. Microbiol., 2013, 3, 106.
51. Peters, K.N.; Dhariwala, M.O.; Hughes Hanks, J.M.; Brown, C.R.; Anderson, D.M. Early apoptosis of macrophages modulated by injection of Yersinia pestis YopK promotes progression of primary pneumonic plague. PLoS. Pathog., 2013, 9 (4), e1003324.
52. Sebbane, F.; Lemaitre, N.; Sturdevant, D.E.; Rebeil, R.; Virtaneva, K.; Porcella, S.F.; Hinnebusch, B.J. Adaptive response of Yersinia pestis to extracellular effectors of innate immunity during bubonic plague. Proc. Natl. Acad. Sci. U. S. A, 2006, 103 (31), 11766-11771.
53. Brubaker, R.R. Interleukin-10 and inhibition of innate immunity to Yersiniae: Roles of Yops and LcrV (V antigen). Infect. Immun., 2003, 71 (7), 3673-3681.
54. Song, D.H.; Lee, J.O. Sensing of microbial molecular patterns by Toll-like receptors. Immunol. Rev., 2012, 250 (1), 216-229.
55. Kingeter, L.M.; Lin, X. C-type lectin receptor-induced NF-kappaB activation in innate immune and inflammatory responses. Cell. Mol. Immunol., 2012, 9 (2), 105-112.
56. Russo, B.C.; Brown, M.J.; Nau, G.J. MyD88-Dependent Signaling Prolongs Survival and Reduces Bacterial Burden during Pulmonary Infection with Virulent Francisella tularensis. Am. J. Pathol., 2013. 183 (4) 1223-1232.
57. Goodyear, A.; Troyer, R.; Bielefeldt-Ohmann, H.; Dow, S. MyD88-dependent recruitment of monocytes and dendritic cells required for protection from pulmonary Burkholderia mallei infection. Infect. Immun., 2012, 80 (1), 110-120.
58. Hughes, M.A.; Green, C.S.; Lowchyj, L.; Lee, G.M.; Grippe, V.K.; Smith, M.F. Jr.; Huang, L.Y.; Harvill, E.T.; Merkel, T.J. MyD88-dependent signaling contributes to protection following Bacillus anthracis spore challenge of mice: Implications for Toll-like receptor signaling. Infect. Immun., 2005, 73 (11), 7535-7540.
59. Viriyakosol, S.; Jimenez, M.P.; Gurney, M.A.; Ashbaugh, M.E.; Fierer, J. Dectin-1 is required for resistance to coccidioidomycosis in mice. MBio., 2013, 4 (1), e00597-12.
60. Parent, M.A.; Wilhelm, L.B.; Kummer, L.W.; Szaba, F.M.; Mullarky, I.K.; Smiley, S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect. Immun., 2006, 74 (6), 3381-3386.
61. Crane, D.D.; Scott, D.P.; Bosio, C.M. Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS. One, 2012, 7 (3), e33349.
62. Zahringer, U.; Lindner, B.; Inamura, S.; Heine, H.; Alexander, C.T. TLR2-promiscuous or specific? A crticial re-evaluation of a receptor expressing apparent broad specificity. Immunobiology, 2008, 213 (3-4), 205-224.
63. Gosu, V.; Basith, S.; Kwon, O.P.; Choi, S. Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. Molecules., 2012, 17 (11), 13503-13529.
64. Shuto, T.; Kato, K.; Mori, Y.; Viriyakosol, S.; Oba, M.; Furuta, T.; Okiyoneda, T.; Arima, H.; Suico, M.A.; Kai, H. Membraneanchored CD14 is required for LPS-induced TLR4 endocytosis in TLR4/MD-2/CD14 overexpressing CHO cells. Biochem. Biophys. Res. Commun., 2005, 338 (3), 1402-1409.
65. Mata-Haro, V.; Cekic, C.; Martin, M.; Chilton, P.M.; Casella, C.R.; Mitchell, T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science, 2007, 316 (5831), 1628-1632.
66. Michaud, J.P.; Halle, M.; Lampron, A.; Theriault, P.; Prefontaine, P.; Filali, M.; Tribout-Jover, P.; Lanteigne, A.M.; Jodoin, R.; Cluff, C.; Brichard, V.; Palmantier, R.; Pilorget, A.; Larocque, D.; Rivest, S. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc. Natl. Acad. Sci. U. S. A, 2013, 110 (5), 1941-1946.
67. Bode, C.; Zhao, G.; Steinhagen, F.; Kinjo, T.; Klinman, D.M. CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines., 2011, 10 (4), 499-511.
68. Hajjar, A.M.; Ernst, R.K.; Fortuno, E.S. III; Brasfield, A.S.; Yam, C.S.; Newlon, L.A.; Kollmann, T. R.; Miller, S.I.; Wilson, C.B. Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS. Pathog., 2012, 8 (10), e1002963.
69. Campbell, J.D.; Cho, Y.; Foster, M.L.; Kanzler, H.; Kachura, M.A.; Lum, J.A.; Ratcliffe, M.J.; Sathe, A.; Leishman, A.J.; Bahl, A.; McHale, M.; Coffman, R.L.; Hessel, E.M. CpG-containing immunostimulatory DNA sequences elicit TNF-α-dependent toxicity in rodents but not in humans. J. Clin. Invest., 2009, 119 (9), 2564-2576.
70. Brown, G.D.; Herre, J.; Williams, D.L.; Willment, J.A.; Marshall, A.S.; Gordon, S. Dectin-1 mediates the biological effects of betaglucans. J. Exp. Med., 2003, 197 (9), 1119-1124.
71. Duckett, N.S.; Olmos, S.; Durrant, D.M.; Metzger, D.W. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect. Immun., 2005, 73 (4), 2306-2311.
72. Skyberg, J.A.; Thornburg, T.; Kochetkova, I.; Layton, W.; Callis, G.; Rollins, M.F.; Riccardi, C.; Becker, T.; Golden, S.; Pascual, D.W. IFN-γ-deficient mice develop IL-1-dependent cutaneous and musculoskeletal inflammation during experimental brucellosis. J. Leukoc. Biol., 2012, 92(2), 375-387.
73. Coulombe, F.; Jaworska, J.; Verway, M.; Tzelepis, F.; Massoud, A.; Gillard, J.; Wong, G.; Kobinger, G.; Xing, Z.; Couture, C.; Joubert, P.; Fritz, J.H.; Powell, W.S.; Divangahi, M. Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity., 2014, 40 (4), 554-568.
74. Pyles, R.B.; Jezek, G.E.; Eaves-Pyles, T.D. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect. Immun., 2010, 78 (4), 1700-1710.
75. Lippmann, J.; Muller, H.C.; Naujoks, J.; Tabeling, C.; Shin, S.; Witzenrath, M.; Hellwig, K.; Kirschning, C.J.; Taylor, G.A.; Barchet, W.; Bauer, S.; Suttorp, N.; Roy, C.R.; Opitz, B. Dissection of a type I interferon pathway in controlling bacterial intracellular infection in mice. Cell Microbiol., 2011, 13 (11), 1668-1682.
76. Pratt, C.L.; Brown, C.R. The role of eicosanoids in experimental Lyme arthritis. Front Cell Infect. Microbiol., 2014, 4, 69.
77. Woolard, M.D.; Hensley, L.L.; Kawula, T.H.; Frelinger, J.A. Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect. Immun., 2008, 76 (6), 2651-2659.
78. Duggan, J.M.; You, D.; Cleaver, J.O.; Larson, D.T.; Garza, R.J.; Guzman Pruneda, F.A.; Tuvim, M.J.; Zhang, J.; Dickey, B.F.; Evans, S.E. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J. Immunol., 2011, 186 (10), 5916-5926.
79. Evans, S.E.; Scott, B.L.; Clement, C.G.; Larson, D.T.; Kontoyiannis, D.; Lewis, R.E.; Lasala, P.R.; Pawlik, J.; Peterson, J.W.; Chopra, A.K.; Klimpel, G.; Bowden, G.; Hook, M.; Xu, Y.; Tuvim, M.J.; Dickey, B.F. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am. J. Respir. Cell Mol. Biol., 2010, 42 (1), 40-50.
80. Walberg, K.; Baron, S.; Poast, J.; Schwartz, B.; Izotova, L.; Pestka, S.; Peterson, J.W. Interferon protects mice against inhalation anthrax. J. Interferon Cytokine Res., 2008, 28 (10), 597-601.
81. Veach, R.A.; Zienkiewicz, J.; Collins, R.D.; Hawiger, J. Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy. PLoS. ONE, 2012, 7 (1), e30527.
82. Wu, C.C.; Sabet, M.; Hayashi, T.; Tawatao, R.; Fierer, J.; Carson, D.A.; Guiney, D.G.; Corr, M. In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. Cell. Immunol., 2008, 251 (2), 78-85.
83. Kournikakis, B.; Mandeville, R.; Brousseau, P.; Ostroff, G. Anthrax-protective effects of yeast beta 1,3 glucans. Med. Gen. Med., 2003, 5 (1), 1.
84. Wu, C.C.; Hayashi, T.; Takabayashi, K.; Sabet, M.; Smee, D.F.; Guiney, D.D.; Cottam, H.B.; Carson, D.A. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl. Acad. Sci. U. S. A, 2007, 104 (10), 3990-3995.
85. Stevens, M.G.; Pugh, G.W. Jr.; Tabatabai, L.B. Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice. Infect. Immun., 1992, 60 (10), 4407-4409.
86. Segura, S.; Gamazo, C.; Irache, J.M.; Espuelas, S. Gamma interferon loaded onto albumin nanoparticles: In vitro and in vivo activities against Brucella abortus. Antimicrob. Agents Chemother., 2007, 51 (4), 1310-1314.
87. Pasquali, P.; Adone, R.; Gasbarre, L.C.; Pistoia, C.; Ciuchini, F. Effect of exogenous interleukin-18 (IL-18) and IL-12 in the course of Brucella abortus 2308 infection in mice. Clin. Diagn. Lab Immunol., 2002, 9 (2), 491-492.
88. Sathiyaseelan, J.; Goenka, R.; Parent, M.; Benson, R.M.; Murphy, E.A.; Fernandes, D.M.; Foulkes, A.S.; Baldwin, C.L. Treatment of Brucella-susceptible mice with IL-12 increases primary and secondary immunity. Cell. Immunol., 2006, 243 (1), 1-9.
89. Boura, P.; Tsapas, G.; Kountouras, J.; Zaharioudaki, E. Interferon-A 2a administration in chronic anergic brucellosis. Hepatogastroenterology, 1995, 42 (6), 919-922.
90. Cheers, C.; Cone, R.E. Effect of polyadenine: Polyuridine on brucellosis in conventional and congenitally athymic mice. J. Immunol., 1974, 112 (4), 1535-1539.
91. Madraso, E.D.; Cheers, C. Polyadenylic acid-polyuridylic acid (poly A : U) and experimental murine brucellosis. II. Macrophages as target cells of poly A : U in experimental brucellosis. Immunology, 1978, 35 (1), 77-84.
92. Zhan, Y.F.; Stanley, E.R.; Cheers, C. Prophylaxis or treatment of experimental brucellosis with interleukin-1. Infect. Immun., 1991, 59 (5), 1790-1794.
93. Sinai, Y.; Kaplun, A.; Hai, Y.; Halperin, B. Enhancement of resistance to infectious diseases by oral administration of brewer's yeast. Infect. Immun., 1974, 9 (5), 781-787.
94. Waag, D.M.; McCluskie, M.J.; Zhang, N.; Krieg, A.M. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect. Immun., 2006, 74 (3), 1944-1948.
95. Easton, A.; Haque, A.; Chu, K.; Patel, N.; Lukaszewski, R.A.; Krieg, A.M.; Titball, R.W.; Bancroft, G.J. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J. Infect. Dis., 2011, 204 (4), 636-644.
96. Takaoka, A.; Wang, Z.; Choi, M.K.; Yanai, H.; Negishi, H.; Ban, T.; Lu, Y.; Miyagishi, M.; Kodama, T.; Honda, K.; Ohba, Y.; Taniguchi, T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature, 2007, 448 (7152), 501-505.
97. Goodyear, A.; Kellihan, L.; Bielefeldt-Ohmann, H.; Troyer, R.; Propst, K.; Dow, S. Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect. Immun., 2009, 77 (4), 1579-1588.
98. Propst, K.L.; Troyer, R.M.; Kellihan, L.M.; Schweizer, H.P.; Dow, S.W. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob. Agents Chemother., 2010, 54 (5), 1785-1792.
99. Reynolds, J.A.; Kastello, M.D.; Harrington, D.G.; Crabbs, C.L.; Peters, C.J.; Jemski, J.V.; Scott, G.H.; Di Luzio, N.R. Glucaninduced enhancement of host resistance to selected infectious diseases. Infect. Immun., 1980, 30 (1), 51-57.
100. Holderness, J.; Schepetkin, I.A.; Freedman, B.; Kirpotina, L.N.; Quinn, M.T.; Hedges, J.F.; Jutila, M.A. Polysaccharides isolated from Acai fruit induce innate immune responses. PLoS ONE, 2011, 6 (2), e17301.
101. Goodyear, A.; Jones, A.; Troyer, R.; Bielefeldt-Ohmann, H.; Dow, S. Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection. J. Immunol., 2010, 184 (3), 1445-1454.
102. Asakrah, S.; Nieves, W.; Mahdi, Z.; Agard, M.; Zea, A.H.; Roy, C.J.; Morici, L.A. Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei. PLoS. Negl. Trop. Dis., 2013, 7 (5), e2212.
103. Wongratanacheewin, S.; Kespichayawattana, W.; Intachote, P.; Pichyangkul, S.; Sermswan, R.W.; Krieg, A.M.; Sirisinha, S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect. Immun., 2004, 72 (8), 4494-4502.
104. Nakajima, R.; Brubaker, R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect. Immun., 1993, 61 (1), 23-31.
105. Cole, L.E.; Mann, B.J.; Shirey, K.A.; Richard, K.; Yang, Y.; Gearhart, P.J.; Chesko, K.L.; Viscardi, R.M.; Vogel, S.N. Role of TLR signaling in Francisella tularensis-LPS-induced, antibodymediated protection against Francisella tularensis challenge. J. Leukoc. Biol., 2011, 90(4), 878-797.
106. Ireland, R.; Olivares-Zavaleta, N.; Warawa, J.M.; Gherardini, F.C.; Jarrett, C.; Hinnebusch, B.J.; Belisle, J.T.; Fairman, J.; Bosio, C.M. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS. Pathog., 2010, 6 (5), e1000921.
107. Lembo, A.; Pelletier, M.; Iyer, R.; Timko, M.; Dudda, J.C.; West, T.E.; Wilson, C.B.; Hajjar, A.M.; Skerrett, S.J. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J. Immunol., 2008, 180 (11), 7574-7581.
108. Pammit, M.A.; Budhavarapu, V.N.; Raulie, E.K.; Klose, K.E.; Teale, J.M.; Arulanandam, B.P. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob. Agents Chemother., 2004, 48 (12), 4513-4519.
109. Elkins, K.L.; Rhinehart-Jones, T.R.; Stibitz, S.; Conover, J.S.; Klinman, D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol., 1999, 162 (4), 2291-2298.
110. Lubick, K.; Radke, M.; Jutila, M. Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: Comparison with TLR agonists. J. Leukoc. Biol., 2007, 82 (5), 1062-1069.
111. LeMessurier, K.S.; Hacker, H.; Chi, L.; Tuomanen, E.; Redecke, V. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS. Pathog., 2013, 9 (11), e1003727.
112. Kafka, D.; Ling, E.; Feldman, G.; Benharroch, D.; Voronov, E.; Givon-Lavi, N.; Iwakura, Y.; Dagan, R.; Apte, R.N.; Mizrachi-Nebenzahl, Y. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int. Immunol., 2008, 20 (9), 1139-1146.
113. Vogels, M.T.; Sweep, C.G.; Hermus, A.R.; van der Meer, J.W. Interleukin-1-induced nonspecific resistance to bacterial infection in mice is not mediated by glucocorticosteroids. Antimicrob. Agents Chemother., 1992, 36 (12), 2785-2789.
114. Hershman, M.J.; Polk, H.C.; Jr.; Pietsch, J.D.; Kuftinec, D.; Sonnenfeld, G. Modulation of Klebsiella pneumoniae infection of mice by interferon-gamma. Clin. Exp. Immunol., 1988, 72 (3), 406-409.
115. Jiang, T.; Zhao, H.; Li, X.F.; Deng, Y.Q.; Liu, J.; Xu, L.J.; Han, J.F.; Cao, R.Y.; Qin, E.D.; Qin, C.F. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res., 2011, 89 (1), 124-126.
116. Rees, D.G.; Gates, A.J.; Green, M.; Eastaugh, L.; Lukaszewski, R.A.; Griffin, K.F.; Krieg, A.M.; Titball, R.W. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res., 2005, 65 (2), 87-95.
117. Gowen, B.B.; Fairman, J.; Dow, S.; Troyer, R.; Wong, M.H.; Jung, K.H.; Melby, P.C.; Morrey, J.D. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: Importance of liposomal delivery and CpG motifs. Antiviral Res., 2009, 81 (1), 37-46.
118. Kohl, S.; Jansen, D.M.; Loo, L.S. Indomethacin enhancement of human natural killer cytotoxicity to herpes simplex virus infected cells in vitro and in vivo. Prostaglandins Leukot. Med., 1982, 9 (2), 159-166.
119. Khor, M.; Lowrie, D.B.; Coates, A.R.; Mitchison, D.A. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br. J. Exp. Pathol., 1986, 67 (4), 587-596.
120. Flynn, J.L.; Goldstein, M.M.; Triebold, K.J.; Sypek, J.; Wolf, S.; Bloom, B.R. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol., 1995, 155 (5), 2515-2524.
121. Gould, C.L.; Sonnenfeld, G. Effect of treatment with interferongamma and concanavalin A on the course of infection of mice with Salmonella typhimurium strain LT-2. J. Interferon Res., 1987, 7 (3), 255-260.
122. Weiss, I.D.; Wald, O.; Wald, H.; Beider, K.; Abraham, M.; Galun, E.; Nagler, A.; Peled, A. IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK celldependent manner. J. Interferon Cytokine Res., 2010, 30 (6), 439-449.
123. Kurtz, R.S.; Roll, J.T.; Czuprynski, C.J. Recombinant human interleukin 1 alpha enhances anti-Listeria resistance in both genetically resistant and susceptible strains of mice. Immunol. Lett., 1988, 18 (4), 289-292.
124. Hirano, T.; Kodama, S.; Kawano, T.; Maeda, K.; Suzuki, M. Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice. FEMS Immunol. Med. Microbiol., 2011, 63 (3), 407-417.
125. Wu, J.; Huang, S.; Zhao, X.; Chen, M.; Lin, Y.; Xia, Y.; Sun, C.; Yang, X.; Wang, J.; Guo, Y.; Song, J.; Zhang, E.; Wang, B.; Zheng, X.; Schlaak, J.F.; Lu, M.; Yang, D. Polyinosinicpolycytidylic acid treatment leads to the interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J. Virol., 2014. 88 (19) 10421-10431.
126. Kende, M. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice. J. Biol. Response Mod., 1985, 4 (5), 503-511.
127. Chen, N.; Warner, J.L.; Reiss, C.S. NSAID treatment suppresses VSV propagation in mouse CNS. Virology, 2000, 276 (1), 44-51.
128. Logue, C.H.; Phillips, A.T.; Mossel, E.C.; Ledermann, J.P.; Welte, T.; Dow, S.W.; Olson, K.E.; Powers, A.M. Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge. Antiviral Res., 2010, 87 (2), 195-203.
129. Zhao, J.; Wohlford-Lenane, C.; Zhao, J.; Fleming, E.; Lane, T.E.; McCray, P.B. Jr.; Perlman, S. Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. J. Virol., 2012, 86 (21), 11416-11424.
130. Baldridge, J.R.; Cluff, C.W.; Evans, J.T.; Lacy, M.J.; Stephens, J.R.; Brookshire, V.G.; Wang, R.; Ward, J.R.; Yorgensen, Y.M.; Persing, D.H.; Johnson, D.A. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): Induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin. Res., 2002, 8 (6), 453-458.
131. Bosio, C.M.; Bielefeldt-Ohmann, H.; Belisle, J.T. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J. Immunol., 2007, 178 (7), 4538-4547.
132. Chase, J.C.; Celli, J.; Bosio, C.M. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect. Immun., 2009, 77 (1), 180-195.
133. Radhakrishnan, G.K.; Yu, Q.; Harms, J.S.; Splitter, G.A. Brucella TIR Domain-containing Protein Mimics Properties of the Toll-like Receptor Adaptor Protein TIRAP. J. Biol. Chem., 2009, 284 (15), 9892-9898.
134. Sweet, C.R.; Conlon, J.; Golenbock, D.T.; Goguen, J.; Silverman, N. YopJ targets TRAF proteins to inhibit TLR-mediated NFkappaB, MAPK and IRF3 signal transduction. Cell. Microbiol., 2007, 9 (11), 2700-2715.
135. Baral, P.; Utaisincharoen, P. Involvement of signal regulatory protein alpha, a negative regulator of Toll-like receptor signaling, in impairing the MyD88-independent pathway and intracellular killing of Burkholderia pseudomallei-infected mouse macrophages. Infect. Immun., 2012, 80 (12), 4223-4231.
136. Fang, H.; Xu, L.; Chen, T.Y.; Cyr, J.M.; Frucht, D.M. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J. Immunol., 2006, 176 (10), 6155-6161.
137. Garg, G.; Kar, P. Management of HCV infection: Current issues and future options. Trop. Gastroenterol., 2009, 30 (1), 11-18.
138. Takeda, K.; Kawai, T.; Nakazawa, Y.; Komuro, H.; Shoji, K.; Morita, K.; Katsuta, T.; Yamamoto, M.; Miyairi, I.; Ohya, Y.; Ishiguro, A.; Onodera, M. Augmentation of antitubercular therapy with IFNgamma in a patient with dominant partial IFNgamma receptor 1 deficiency. Clin. Immunol., 2014, 151 (1), 25-28.
139. Koster, F.T.; Williams, J.C.; Goodwin, J.S. Cellular immunity in Q fever: Modulation of responsiveness by a suppressor T cellmonocyte circuit. J. Immunol., 1985, 135 (2), 1067-1072.
140. Walker, T.S.; Dersch, M.W.; White, W.E. Effects of typhus rickettsiae on peritoneal and alveolar macrophages: Rickettsiae stimulate leukotriene and prostaglandin secretion. J. Infect. Dis., 1991, 163 (3), 568-573.